Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

JAPANESE FUNDING OF U.S. UNIVERSITY BIOMEDICAL R&D: NINE FIRMS

Executive Summary

JAPANESE FUNDING OF U.S. UNIVERSITY BIOMEDICAL R&D: NINE FIRMS are providing funding to U.S. academic centers and start-up firms, according to information in a new consulting report on the Japanese involvement in the U.S. drug business. The stufy by the SRI International Health Industries Practice is entitled, "Japanese Pharmaceutical Internationalization." The study observes that one of the major trends in the Japanese effort to expand into international businesses is that "many of the major Japanese firms have moved to set up 'R' (discovery research) agreements with important U.S. academic research centers" or "have established networks with both commercial and academic entities to deal with new products." Among the companies cited by SRI as taking on collaborative research agreements are Ajinimoto USA, Chugai, Daiichi, Mitsubushi, Shiseido, Otsuka, Yamanouchi, Kirin and Fujirebio. Chugai's Oct. 3 investment of $30 mil. in the Vertex immunophilin program exemplifies the type of early stage research collaboration. While many of the Japanese firms appear to be taking a slow, small-step approach in U.S. expansion through the R&D collaborations, SRI noted that several of the largest Japanese firms have taken the next step toward large-scale acquisitions of existing businesses. SRI described Fujisawa as the most internationalized of the Japanese firms surveyed. The company has concentrated on establishing its own independent base of U.S. operations, SRI observed, complete with R&D facilities at Fujisawa USA, Inc. Otsuka is characterized by SRI as having "mounted the most aggressive internationalization effort." The company has extensive interests and is part of a privately-owned $4 bil. annual sales conglomerate with 20-plus companies. SRI points out that Otsuka has engaged in "widely diversified" investments purchasing a contrast media and glycoconjugates research firm in Seattle (Oncomembrane) and the $100 mil. Pharmavite vitamin business, building its own two research facilities in Maryland, and maintaining affiliations with several American universities. Otsuka's first home-grown NDA for the U.S. market is expected to be a congestive heart failure product, vesnarinone.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS018172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel